Categories Earnings, Health Care, Markets

Pfizer boosts oncology portfolio with $10-Bil acquisition of Array Biopharma

In a sign that the consolidation wave that swept in the pharmaceutical industry last year is likely to continue, Pfizer (NYSE: PFE) announced the acquisition of Array Biopharma (ARRY) for $10.64 billion in an all-cash transaction.  Shares of Array surged in premarket-trading Monday following the report, while Pfizer gained modestly.

Array, a clinical stage drug developer which has been collaborating with Merck (MRCK) and Pfizer for research on several cancer therapies, will strengthen Pfizer’s oncology portfolio. The Boulder, Colorado-based Array has a pipeline of multiple drug candidates targeting various types of cancers.

Array, which has been collaborating with Pfizer for research in several cancer therapies, will strengthen the latter’s oncology portfolio

Currently, Array’s most valuable asset is its FDA approved drug for skin cancer. Pfizer has reportedly been looking for new products to overcome the softness in the sales of its popular painkiller Lyrica, which is facing intense competition. Of late, the company has been focusing a lot on cancer.

The takeaway

The offer price is equivalent to $48 per each share of Array and represents a 62% premium to the last closing price. According to Pfizer’s management, the transaction will be closed in the second half of 2019. It is expected to be dilutive to Pfizer’s adjusted earnings by 4-5 cents per share until next year. By the start of 2022, it will start contributing to earnings.

Pipeline

Last year, a drug developed by Array for the treatment of a severe form of skin cancer received approval from the FDA. The formulation, to be administered in combination orally, is now available for patients in the US. Another promising candidate from Array is its triple combo therapy for the treatment of colorectal cancer, which is currently being tested.

Impressive Q1

In the first quarter, earnings and revenues of Pfizer increased sharply to $0.85 per share and $13.1 billion respectively and topped the expectations, on the strength of the pharma business. The main growth driver was the Prevnar-Prevenar combo, while the slump in the sales of pain drug Lyrica turned a dampener.

Also see: Array BioPharma Q3 2019 Earnings Conference Call Transcript

Array shares soared 57% early Monday, following the announcement, and hit a record high. The uptrend was sustained after trading started. In the past six months, the value more than doubled. Though Pfizer moved up modestly initially, the stock pared the gains later.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

One thought on “Pfizer boosts oncology portfolio with $10-Bil acquisition of Array Biopharma

Leave a Reply

Your email address will not be published. Required fields are marked *

Add Comment
Loading...

Cancel
Viewing Highlight
Loading...
Highlight
Close
Top